Patient Care Associate Trainee

Which health systems have chief AI officers. Table of contents. As hospitals and health systems further embed AI into healthcare delivery, they are increasingly appointing chief AI officers or equivalent senior executives with dedicated responsibility for AI governance, implementation and oversight, reflecting a broader trend of health systems chief AI officers taking on formalized C-suite roles. Why health systems chief AI officers roles are growing. The growing presence of these roles reflects the industry's recognition that AI may pose risks to patient safety, professional liability and regulatory compliance, and thus warrants cross-functional leadership at the highest levels. Below is a look at healthcare organizations with dedicated AI leadership. Academic medical centers leading with health systems chief AI officers. Ann & Robert H. Lurie Children's Hospital of Chicago named Rajiv Kolagani as its chief data and AI officer. BJC Health System and WashU Medicine in St. Louis appointed two leaders: Philip R.O. Payne, PhD, as the inaugural chief health AI officer of WashU Medicine and BJC, and Deborah O'Dell as chief data & analytics officer at BJC. Major health systems with chief AI officers on the west coast. Cedars-Sinai in Los Angeles appointed Mouneer Odeh as its inaugural chief artificial intelligence officer at the end of 2024. City of Hope in Duarte, Calif., named Nasim Eftekhari system vice president and chief AI and analytics officer. UCLA Health named Paul J. Lukac, MD, as its chief AI officer, while UCSF Health named Sara Murray, MD, as chief health AI officer. UC San Diego Health named Karandeep Singh, MD, as its inaugural chief health artificial intelligence officer, and UCI Health in Orange, Calif., named Deepti Pandita, MD, as its chief medical informatics and AI officer. Kaiser Permanente's approach to AI leadership. Kaiser Permanente in Oakland, Calif., has Daniel Yang, MD, serving as vice president of artificial intelligence and emerging technologies, a title distinct from the "chief AI officer" designation used at many peer organizations. Midwest and southern health systems chief AI officers. Cleveland Clinic appointed Ben Shahshahani, PhD, as its first vice president and chief artificial intelligence officer in August 2024. Mayo Clinic in Rochester, Minn., appointed Micky Tripathi, PhD, as its chief AI implementation officer, while Mayo Clinic Arizona in Phoenix separately named Bhavik Patel, MD, as chief AI officer. Mercy in St. Louis named Byron Yount, PhD, as chief data and artificial intelligence officer and vice president of transformation operations. Additional regional health systems naming AI chiefs. Baptist Health System in Louisville, Ky., named Brett Oliver, MD, as its chief medical information and AI officer. Bon Secours Mercy Health in Cincinnati named Dylan Clark as its chief analytics and artificial intelligence officer. University of Utah Health in Salt Lake City appointed Kensaku Kawamoto, MD, PhD, as its first chief health AI transformation officer. UT Southwestern Medical Center in Dallas named Warren D'Souza, PhD, as its inaugural chief artificial intelligence officer, and VCU Health in Richmond, Va., named Alok Chaudhary as vice president and chief data and artificial intelligence officer. Children's Hospitals and Denver Health's AI Leadership. Children's National Hospital in Washington, D.C., named Alda Mizaku as vice president and chief data and AI officer. Denver Health named Daniel Kortsch, MD, as its associate chief of AI and digital health. Hackensack Meridian Health in Edison, N.J., named David Arnold as its senior vice president and chief AI and data officer. Variation in title and scope across these health systems chief AI officers. Across this list, titles vary meaningfully, from "chief AI officer" to "chief health AI officer" to "vice president of artificial intelligence and emerging technologies," reflecting differing organizational structures and how each health system chooses to position AI leadership relative to existing informatics, data, and analytics functions. What this wave of health systems chief AI officers means going forward. With more than 20 major health systems now represented on this list, spanning academic medical centers, children's hospitals, and regional systems across the country, the appointment of dedicated AI leadership appears to have become a standard organizational response to AI's growing role in clinical and administrative operations. Given the cross-functional nature of these roles, spanning patient safety, professional liability, and regulatory compliance, other health systems without a formally designated AI chief may increasingly feel competitive pressure to establish similar positions. What to watch going forward. As this list continues to grow, with Becker's actively soliciting additional health systems for inclusion, industry observers will likely watch which organizational models, dedicated chief AI officer roles versus AI responsibilities folded into existing chief medical information officer or chief data officer positions, prove most effective at balancing innovation with the governance and compliance demands these executives are tasked with managing. Given how recently many of these appointments occurred, with several dating to only the past one to two years, this health systems chief AI officers trend appears to still be in its early, rapidly evolving phase across the healthcare industry.

WashU announces new academic-industry collaboration with Bristol Myers Squibb. Multiyear program will provide hands-on training at the pharmaceutical company, fund translational neuroscience research at WashU Washington University in St. Louis and Bristol Myers Squibb have formed a multiyear collaboration to foster scientific exchange between academia and industry in the field of neuroscience. Through this agreement, WashU medical and research trainees will have opportunities to work alongside Bristol Myers Squibb teams on select drug development projects. The collaboration builds on a long-standing research relationship aimed at combining WashU's expertise in fundamental and clinical research in neurodegenerative diseases with Bristol Myers Squibb's extensive experience in drug discovery and development. It also will provide unique opportunities for WashU Medicine trainees to gain embedded industry experience. "This partnership represents a powerful model for how academia and industry can work together to advance neuroscience," said Doug E. Frantz, WashU's vice chancellor for innovation and commercialization. "By pairing our strengths in fundamental and clinical neuroscience with Bristol Myers Squibb's deep expertise in drug development, we have an opportunity to accelerate breakthrough discoveries toward meaningful therapies for patients. At the same time, integrating our residents and fellows within Bristol Myers Squibb ensures we are training the next generation of physician-scientists in the full continuum of translational science." Each year, the program will provide funding to support up to three visiting fellows at Bristol Myers Squibb and three translational research programs at WashU in the neurosciences, with the goal of developing potential new therapeutics for neurological, neuromuscular, neuroinflammatory and psychiatric conditions. "This collaboration reinforces our commitment to working together with the goal to advance innovation that can help address significant unmet needs in neurodegenerative and neuropsychiatric diseases," said Peter Paine, head of strategic partnerships for Bristol Myers Squibb. "These conditions represent some of the greatest health challenges of our time, and we look forward to working with WashU to pursue transformational treatments for patients." WashU faculty have long collaborated with Bristol Myers Squibb on specific studies or within larger academia-industry initiatives such as the Neurofilament Light Consortium, a collaboration among WashU Medicine, University College London and several pharmaceutical companies, including Bristol Myers Squibb, to investigate neurodegenerative diseases. The new collaboration creates a formal structure to form and fund research projects in priority areas for both WashU and Bristol Myers Squibb. The goal of the agreement is ultimately to advance the field of neuroscience in ways that lead to improved treatments and patient outcomes. Private-sector partnerships with universities are usually narrow in scope, funding a pre-defined set of projects. In contrast, the high-level joint commitment of this new collaboration focuses on training the next generation of leaders in neuroscience to be proficient in both academic and industry settings. Melanie Roewe, associate vice chancellor of research administration at WashU, said that the mutual enthusiasm was reflected in the speed and ease with which the agreement came together. "This is an elevated relationship, different from most collaborations," said Roewe. "Both sides are invested in finding new and productive ways to work together and continually furthering what this collaboration can achieve." Program participation. Individuals interested in participating in the visiting fellows program or the translational neuroscience research program are encouraged to submit an expression of interest by Sept. 1. For additional information regarding eligibility, participation and the expression-of-interest process, reach out to Mark Van Horn, senior director of business development, Strategic External Projects and Outreach, at [email protected]. About WashU Medicine WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with more than 3,000 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 83% since 2016. Together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently among the top five in the country, with more than 2,000 faculty physicians practicing at 130 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children's hospitals - the academic hospitals of BJC HealthCare - and Siteman Cancer Center, a partnership between BJC HealthCare and WashU Medicine and the only National Cancer Institute-designated comprehensive cancer center in Missouri. WashU Medicine physicians also treat patients at BJC's community hospitals in its region. With a storied history in MD/PhD training, WashU Medicine recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

Global AI movements & new biological pathways. Focus: Aligning Glassbury AI's engineering approach with the massive global computational shift and a newly discovered cellular death mechanism. 1. "The C-BRAIN consortium: what an 'AI biomedical research scientist' means for Glassbury's tech stack" * The Hook: On July 13, 2026, a global coalition of academic centers (led by WashU Medicine) and pharma giants launched C-BRAIN. Its mission? Building open-source AI tools to attack the notorious 99% failure rate of neurodegenerative clinical trials by synthesizing "dark" (unpublished) data and clinical literature. * The Angle: Write an insider piece on how Glassbury AI views this watershed moment. Explain that the era of isolated, proprietary "black box" medical AI is ending. Detail how Glassbury's own pipelines plan to leverage and interface with C-BRAIN's open-source frameworks, establishing Glassbury as an early adopter of standardized, collaborative medical AI. * Why It Matters Now: This is the biggest medical-AI news of the summer. Aligning Glassbury with a major global consortium shows that your team is at the absolute forefront of industry standards.